Trilogy Capital’s Opus Genetics IRD Stock Holding History

Trilogy Capital’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4	Closed	–	–	591
2018 Q3	$0	Hold	4	–	–	﹤0.01%	663
2018 Q2	$0	Hold	4	–	–	﹤0.01%	631
2018 Q1	$0	Buy	+4	New	+$363	﹤0.01%	514

Other funds holding IRD

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return

Trilogy Capital's IRD Position: Q4 2018 in Review

Trilogy Capital sold out of Opus Genetics (IRD) in Q4 2018, closing a stake of 4 shares.

Trilogy Capital first reported a position in IRD in Q1 2018 and held it in 3 quarters. The position peaked at $0 in Q3 2018. 29 funds tracked by Wall St. Rank hold IRD as of Q4 2018.

Trilogy Capital reported no remaining Opus Genetics position as of Q4 2018 after selling out during the quarter.
Trilogy Capital sold 4 Opus Genetics shares in Q4 2018.
Trilogy Capital first reported a position in Opus Genetics in Q1 2018 and held it in 3 quarters.
Trilogy Capital's Opus Genetics position peaked at $0 in Q3 2018.
29 funds tracked by Wall St. Rank held Opus Genetics as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.